Stay updated with the latest glucagon-like-peptide-1-receptor-agonist news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on glucagon-like-peptide-1-receptor-agonist topics.
SCHOTT, a leader in specialty glass, initiates local production of high-precision glass tubing for syringes and cartridges in Gujarat, India. This marks a significant step in India's pharmaceutical sector, aligning with the 'Make in India' initiative, enhancing SCHOTT's role in the Asian market. In a notable development in India's pharmaceutical landscape, SCHOTT has successfully commenced local production of high-precision glass tubing for syringes and cartridges at its Jambusar, Gujarat facil ...Read More >
Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular weight-loss drug Wegovy over fears of falling behind rival Eli Lilly in the potentially huge market, two sources familiar with the plans told Reuters. Officials at the Danish drugmaker have said Wegovy might be introduced in India in 2026 once regulatory approvals are in hand and there is sufficient supply. More recently, Novo's India team proposed moving the launch to nex ...Read More >
New Delhi, Nov 26: The popular glucagon-like peptide-1 (GLP-1) receptor agonists known to help in weight loss as well as manage blood sugar can also protect the kidneys, regardless of diabetes status, finds a study led by an Indian-origin researcher. Originally developed to treat diabetes, GLP-1 receptor agonists have significant benefits in people with and without diabetes, according to the study published in The Lancet Diabetes & Endocrinology. The drug stimulates insulin production and low ...Read More >
Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.